Northwestern Mutual Wealth Management Co. Has $78,000 Position in LeMaitre Vascular, Inc. $LMAT

Northwestern Mutual Wealth Management Co. reduced its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 13.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 929 shares of the medical instruments supplier’s stock after selling 140 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in LeMaitre Vascular were worth $78,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. AlphaQuest LLC grew its holdings in shares of LeMaitre Vascular by 9,787.2% during the first quarter. AlphaQuest LLC now owns 8,503 shares of the medical instruments supplier’s stock worth $713,000 after purchasing an additional 8,417 shares during the last quarter. EntryPoint Capital LLC grew its holdings in shares of LeMaitre Vascular by 22.5% during the first quarter. EntryPoint Capital LLC now owns 5,438 shares of the medical instruments supplier’s stock worth $456,000 after purchasing an additional 998 shares during the last quarter. Credit Agricole S A grew its holdings in shares of LeMaitre Vascular by 80.1% during the first quarter. Credit Agricole S A now owns 18,877 shares of the medical instruments supplier’s stock worth $1,584,000 after purchasing an additional 8,393 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of LeMaitre Vascular during the first quarter worth $50,000. Finally, Aptus Capital Advisors LLC bought a new stake in shares of LeMaitre Vascular during the first quarter worth $4,483,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $97.49 on Friday. The business’s 50-day simple moving average is $88.64 and its 200 day simple moving average is $86.20. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of 47.33, a P/E/G ratio of 2.51 and a beta of 0.79. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.03. The business had revenue of $63.15 million for the quarter, compared to analysts’ expectations of $62.48 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. As a group, research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were issued a $0.20 dividend. The ex-dividend date was Thursday, August 21st. This represents a $0.80 annualized dividend and a yield of 0.8%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 38.83%.

Insider Transactions at LeMaitre Vascular

In related news, Director John A. Roush sold 6,561 shares of the firm’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the transaction, the director owned 2,916 shares in the company, valued at $269,875.80. This trade represents a 69.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the firm’s stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at approximately $274,104. This represents a 46.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 120,815 shares of company stock worth $11,280,206 in the last ninety days. 9.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on LMAT shares. Barrington Research upgraded LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 target price on the stock in a report on Wednesday, August 6th. Cantor Fitzgerald increased their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $97.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.